Actively Recruiting
Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction
Led by Kafrelsheikh University · Updated on 2025-09-30
220
Participants Needed
1
Research Sites
18 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the effect of sacubitril/valsartan in patients with prosthetic heart valves with heart failure with reduced ejection fraction (HFrEF).
CONDITIONS
Official Title
Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Both males and females can participate
- History of prosthetic heart valve
- Diagnosed with heart failure with reduced ejection fraction (LVEF ≤ 40%) and NYHA functional class II-IV
You will not qualify if you...
- Hemodynamic instability
- Use of circulatory auxiliary circulation device
- Severe liver problems (alanine aminotransferase >120 U/L)
- Severe kidney problems (estimated glomerular filtration rate <30 mL/min)
- Blood pressure below 100/60 mmHg
- Serum potassium level greater than 5.3 mmol/L
- Severe pulmonary hypertension
- Malignant arrhythmia
- Malignant tumor
- History of hereditary or primary angioedema
- Serious adverse drug reactions or serious complications during treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Kafrelsheikh University
Kafr ash Shaykh, Kafrelsheikh, Egypt, 33516
Actively Recruiting
Research Team
M
Mohammed A Hammad, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here